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Mutations in X-linked CDKL5 gene have been associated to an ultra-rare human disease, now which affects in 
majority girls and is almost always associated to early-onset epilepsy and a severe mental retardation. 
Amongst many other functions, CDKL5 mutations were associated with the nuclear accumulation of HDAC4, 
which results in the silencing of BDNF expression [Trazzi et al. 2016] potentially explaining several 
neurodevelopmental alterations associated with CDD. Furthermore, fibroblasts derived from CDD patients 
displayed an aberrant localization of Nrf2 (a master regulator of antioxidant genes expression) and were 
uncapable of facing even moderate oxidative stresses [Pecorelli et al., 2015]. A critical review of the recent 
literature highlighted the ability of sulforaphane (SFN, an isothiocyanate derivative present in broccoli sprouts 
at high concentration) to epigenetically enhance BDNF production in both wild type and 3 x Tg-AD primary 
neurons, thus activating the TrkB dependent signaling pathways [Kim et al. 2017]. It was demonstrated that 
this action was related to a clear inhibition of total histone deacetylase activity (HDACs). Moreover, BDNF was 
recently demonstrated to induce the hippocampal nuclear translocation of Nrf2, which ends up in neurons 
better suited to face oxidative stress related to ROS production [Bruna et al., 2018]. On this background, we 
elaborated a working hypothesis on the benefit of using SNF treatment in CDD patients. The outcomes of SNF 
treatment on one 8 years old CDKL5 girl will be presented. 
 
 
 
 
